Annual Reports

 
Quarterly Reports

 
8-K

  • 8-K (Nov 17, 2017)
  • 8-K (Oct 26, 2017)
  • 8-K (Oct 11, 2017)
  • 8-K (Aug 7, 2017)
  • 8-K (Jul 27, 2017)
  • 8-K (May 11, 2017)

 
Other

Boston Scientific 8-K 2005

Documents found in this filing:

  1. 8-K
  2. Ex-99.1
  3. Graphic
  4. Graphic
WWW.EXFILE.COM, INC. -- 13663 -- BOSTON SCIENTIFIC CORP. -- FORM 8-K



 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 1, 2005

BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in charter)

DELAWARE
1-11083
04-2695240
(State or other
(Commission
(IRS employer
jurisdiction of
file number)
identification no.)
incorporation)
   

One Boston Scientific Place, Natick, Massachusetts
01760-1537
(Address of principal executive offices)
(Zip code)

Registrant’s telephone number, including area code:  (508) 650-8000


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the fling obligation of the registrant under any of the following provisions:

o             Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o             Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o             Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o             Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 



 

 

 

ITEM 8.01.

OTHER EVENTS.

 

On July 1, 2005, a jury in the United States District Court in Delaware found that Johnson & Johnson’s CYPHER drug-eluting stent infringes one of our patents related to polymer coatings, and that Johnson & Johnson’s CYPHER, Bx VELOCITY, Bx SONIC and GENESIS stents infringe another patent covering stent design. The jury also upheld the validity of both patents. A hearing to determine damages and any other relief will be held at a later date.

 

 

 

 

ITEM 9.01.

FINANCIAL STATEMENTS AND EXHIBITS.

 

99.1

Press Release dated July 1, 2005

 

 

 

 



 


SIGNATURE


Pursuant to the requirements of the Securities and Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
  BOSTON SCIENTIFIC CORPORATION
 
 
 
 
 
 
Date: July 7, 2005 By:   /s/ Lawrence J. Knopf
 
Lawrence J. Knopf
  Vice President and Assistant General Counsel 

 



 
 

 

 

INDEX TO EXHIBITS

 

 

EXHIBIT  

NUMBER

DESCRIPTION

 

99.1

Press Release dated July 1, 2005

 

 

 

 

 

 

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki